AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02181075 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Post-LTLD Biopsy of Target Liver Tumour
Study NCT02181075 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Post-LTLD+FUS (Post-FUS) Biopsy of Target Liver Tumour
Study NCT02181075 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermometry of Target Tumour
Description: A clinically approved thermistor or thermocouple was placed in the target liver tumour for real-time thermometry.
Study NCT03509766 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Histamine skin testing
Description: skin testing using histamine
Study NCT02921646 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Measure of resting energetic expenditure
Description: measure of resting energetic expenditure
Study NCT01406327 — intervention group
Intervention type: DRUG
Intervention: Ambrisentan
Description: Ambrisentan
Study NCT01519635 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aliskiren
Description: Drug therapy will be started with an initial 2 weeks on Aliskiren 150 mg followed by a titration to 300 mg Aliskiren if the treatment is well tolerated. A first baseline measurements will be performed before initiating therapy and a second after 8 weeks of treatment (24h after last drug intake) to assess the chronic effect.
Study NCT01519635 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide
Description: Drug therapy will be started with an initial 2 weeks HCTZ 12.5 mg followed by a titration to 25 mg HCTZ if the treatment is well tolerated. A first baseline measurements will be performed before initiating therapy and a second after 8 weeks of treatment (24h after last drug intake) to assess the chronic effect.
Study NCT03179488 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal TENS
Description: Spinal TENS stimulation over back through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
Study NCT03179488 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: Sham stimulation over back through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
Study NCT04237831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986259
Description: Specified Dose on Specified Days
Study NCT02689505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 836880
Study NCT00219362 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: one injection of vCP1452 at W0, W4, W8 and W20
Study NCT00219362 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: one injection of vCP1452 at W4, W8 and W20
Study NCT00219362 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: one injection of placebo at W0, W4, W8, W20 or at W4, W8,W20
Study NCT01966458 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HeartWare® VAS (HVAD)
Description: The HeartWare® VAS is an implantable centrifugal pump that was designed to provide flows up to 10 L/min in a small device that is both lightweight and simple to use.
Study NCT01966458 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control LVAD
Description: Any FDA-approved LVAD for destination therapy.
Study NCT03194165 — intervention group
Intervention type: BIOLOGICAL
Intervention: Dolutegravir
Description: Dosage
Study NCT03194165 — intervention group
Intervention type: BIOLOGICAL
Intervention: Raltegravir
Description: Dosage
Study NCT03194165 — intervention group
Intervention type: BIOLOGICAL
Intervention: Rilpivirine
Description: Dosage
Study NCT03194165 — intervention group
Intervention type: BIOLOGICAL
Intervention: Nevirapine
Description: Dosage
Study NCT03194165 — intervention group
Intervention type: BIOLOGICAL
Intervention: Atazanavir
Description: Dosage
Study NCT03194165 — intervention group
Intervention type: BIOLOGICAL
Intervention: Darunavir
Description: Dosage
Study NCT03194165 — intervention group
Intervention type: BIOLOGICAL
Intervention: Ritonavir
Description: Dosage
Study NCT01133912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel, gemcitabine, lapatinib
Description: Patients receive paclitaxel and gemcitabine intravenously (iv) on day 1 and 8, and oral lapatinib once daily. Lapatinib with fixed dose will be given once a day p.o. from day 1 without resting during each cycle. The starting doses of paclitaxel 80mg/m2 and gemcitabine 1000mg/m2 iv, on day 1 and 8, and lapatinib 1000mg p.o., daily (dose level 1) will be administered every 21 days.
Study NCT02704988 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Carnoy Solution
Description: The subjects in this group will undergo intervention by having surgery (colorectal cancer resection) and lymph node clearing technique with Carnoy solution
Study NCT02704988 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: GEWF Solution
Description: The subjects in this group will undergo intervention by having surgery (colorectal cancer resection) and lymph node clearing technique with GEWF solution
Study NCT03592082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismuth Subsalicylate
Description: BSS 524 mg ((2) 262 mg tablets) given four times per day for 14 days
Study NCT03592082 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard antibiotic therapy
Description: antibiotic therapy administered per standard protocol
Study NCT02268214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Tablets
Study NCT04664322 — intervention group
Intervention type: DEVICE
Intervention: non invasive ventilation and high flow nasal canulae oxygen therapy
Description: patients with hypoxemic acute respiratory failure received alternatively non invasive ventilation and high flow nasal canulae oxygen therapy
Study NCT03286153 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ideal Body Weight First
Description: Randomized to receive 50 U/kg (+/- 20%) of the factor product participants routinely use based on ideal body weight. For participants age 12-19, ideal weight is calculated using the McLaren method. For participants age 20 and over, ideal weight is calculated using the following equation: \[50kg + (2.3kg\*every inch over 5 feet)\].
Study NCT03286153 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Actual Body Weight First
Description: Randomized to receive 50 U/kg (+/- 20%) of the factor product participants routinely use based on actual body weight.
Study NCT01755533 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rural curriculum
Description: Students in schools randomly assigned to this condition receive the rural version of the curriculum.
Study NCT01755533 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Classic curriculum
Description: Students in schools randomly assigned to this condition receive the classic version of the curriculum.
Study NCT01366820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNZ-2566
Description: Solution for intravenous infusion.~Intravenous bolus infusion over 10 minutes followed by a continuous intravenous maintenance infusion for a total of 72 consecutive hours.
Study NCT01366820 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium Chloride 0.9% Injection
Study NCT06165276 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal (Groups A, C, Y and W-135) Polysaccharide Tetanus Protein Conjugate Vaccine (TetraMen-T).
Description: Pharmaceutical form:suspension for injection-Route of administration:Intramuscular (IM)
Study NCT06165276 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal Group C-CRM197 Conjugate Vaccine
Description: Pharmaceutical form:suspension for injection-Route of administration:Intramuscular (IM)
Study NCT01409447 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biphasic osteochondral composite
Description: We had previously developed a biphasic osteochondral composite as the construct for chondrocyte implantation. We further conducted this feasibility study of such device to treat patients with osteochondral lesion of the knee joints.
Study NCT04829149 — intervention group
Intervention type: OTHER
Intervention: Observational
Description: Statin therapy group and Rosuzet tablet group
Study NCT01745367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivozanib Hydrochloride
Study NCT01745367 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Study NCT01745367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Study NCT01745367 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT01909999 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Osteogenic markers Evaluation
Description: The collection of peri-implant crevicular fluid (PICF) was performed immediately after implant insertion (Baseline) and after 7, 15, 30, 60, 90 and 120 days. The site to be collected was dried and isolated with sterile gauze. PICF was collected at four sites per implant using absorbent paper strips (Periopaper, Oralflow, Smithtown, New York). The volume of fluid was measured immediately with the aid of Periotron (Oraflow, Smithtown, New York) and conditioned at 400uL of PBS buffer + 0.05% Tween and then frozen at -80°C.~The levels of the peri-implant osteogenic markers (OPG, OCN, OPN, TGF-α, and PTH) were determined using the LUMINEX/Magpix system (HBN1A-51K and HCCBP1MAG-58K, Millipore Corporation, Billerica, MA, USA).
Study NCT01909999 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Osteogenic markers Evaluation
Description: The collection of peri-implant crevicular fluid (PICF) was performed immediately after implant insertion (Baseline) and after 7, 15, 30, 60, 90 and 120 days. The site to be collected was dried and isolated with sterile gauze. PICF was collected at four sites per implant using absorbent paper strips (Periopaper, Oralflow, Smithtown, New York). The volume of fluid was measured immediately with the aid of Periotron (Oraflow, Smithtown, New York) and conditioned at 400uL of PBS buffer + 0.05% Tween and then frozen at -80°C.~The levels of the peri-implant osteogenic markers (OPG, OCN, OPN, TGF-α, and PTH) were determined using the LUMINEX/Magpix system (HBN1A-51K and HCCBP1MAG-58K, Millipore Corporation, Billerica, MA, USA).
Study NCT01909999 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Clinical parameters evaluation
Description: The following parameters were assessed:~1. Peri-implant sulcus depth (PISD): distance from the margin of the peri-implant mucosa to the bottom of the peri-implant sulcus;~2. Modified Bleeding on Probing Index: the presence or absence of bleeding after 10 seconds on probing around implants.
Study NCT01909999 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Clinical parameters evaluation
Description: The following parameters were assessed:~1. Peri-implant sulcus depth (PISD): distance from the margin of the peri-implant mucosa to the bottom of the peri-implant sulcus;~2. Modified Bleeding on Probing Index: the presence or absence of bleeding after 10 seconds on probing around implants.
Study NCT01909999 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implant instalation
Description: The surgeries, as well as all postoperative follow-up, were performed at the dental clinic of UNIP-SP. Surgical areas were anesthetized (2% mepivacaine with 1:100,000 epinephrine) and mucoperiosteal incisions in the alveolar ridge mucosa were made. The surgical sequence follow the protocol described by the implant company supplier of implants (SIN - São Paulo, SP, BR). In all cases, for maxilla rehabilitation, 6 implants were installed, while, for mandible, 5 were used.
Study NCT01909999 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Implant instalation
Description: The surgeries, as well as all postoperative follow-up, were performed at the dental clinic of UNIP-SP. Surgical areas were anesthetized (2% mepivacaine with 1:100,000 epinephrine) and mucoperiosteal incisions in the alveolar ridge mucosa were made. The surgical sequence follow the protocol described by the implant company supplier of implants (SIN - São Paulo, SP, BR). In all cases, for maxilla rehabilitation, 6 implants were installed, while, for mandible, 5 were used.
Study NCT01909999 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prosthesis installation
Description: The patients in the IM Group received Brånemark protocol prosthesis within 3 days after the implant. The implants were first molded and the models sent for prosthesis confection (LABDENTAL, São Paulo, SP, Brazil). All prosthesis used straight mini-abutments (SIN, São Paulo, SP), that ranged from 1mm to 4mm in height, whose were tightened with 20N of torque, followed by occlusal adjustment and clinical monitoring
Study NCT01909999 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Suture
Description: Soft tissues sutures were done using absorbable polygalactin 910 suture.
Study NCT02268214 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for dapagliflozin
Description: Tablets
Study NCT02165930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
Study NCT00501202 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: twice daily for 4 weeks
Study NCT00501202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RWJ-333369 (carisbamate)
Description: 200 mg tablet twice daily for 4 weeks
Study NCT02694315 — intervention group
Intervention type: OTHER
Intervention: Bishop score
Description: calculation of modified Bishop score in numbers by digital vaginal examination
Study NCT02694315 — intervention group
Intervention type: OTHER
Intervention: cervical length
Description: measuring cervical length by trans-vaginal ultrasound
Study NCT00774631 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mild induced hypothermia (32-34°C)
Description: Mild Induced hypothermia:~Investigators are advised to use the cooling techniques as used in patients with cardiac arrest. Thus, the choice of cooling method will be left to investigators. Hypothermia will be induced by cold saline infusion as described in appendix 5 \[6, 48\]. Core temperature will be monitored by oesophageal probe and maintained between 32°C and 34°C during 48 hours and followed by strictly passive rewarming. During this phase of treatment, patients will receive deep sedation associated with neuromuscular blockers. Centers participating to the trial will have expertise in cooling methods.
Study NCT00774631 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: local recommendations and guidelines
Description: Investigational procedure:~This study evaluates the impact of mild induced hypothermia (32-34°C) during 48 hours followed by passive rewarming according to recommendations described in appendix. All treatment will be according to local recommendations and guidelines of medical societies and literature. Physicians are advised to use these recommendations; however, the best treatment option for the individual patient should be used.~Controls will receive standard care and will be also be deeply sedated for 48 hours.
Study NCT02501603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: afatinib
Description: Afatinib 40mg daily oral administration
Study NCT02501603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Paclitaxel 80mg/m2 IV weekly (day 1,8,15)
Study NCT00213148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole 1 mg
Description: Subjects will be administered orally with 1 mg of anastrozole once daily for 5 days in Cycle 1, 2 and 3 (each cycle = approximately 1 month).
Study NCT00213148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole 5 mg
Description: Subjects will be administered orally with 5 mg of anastrozole once daily for 5 days in Cycle 1, 2 and 3 (each cycle = approximately 1 month).
Study NCT00213148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole 10 mg
Description: Subjects will be administered orally with 10 mg of anastrozole once daily for 5 days in Cycle 1, 2 and 3 (each cycle = approximately 1 month).
Study NCT00213148 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomiphene Citrate 50 mg
Description: Subjects will be administered orally with 50 mg of clomiphene citrate once daily for 5 days in Cycle 1, 2 and 3 (each cycle = approximately 1 month).
Study NCT00213148 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomiphene Citrate 100 mg
Description: Subjects will be administered orally with 100 mg of clomiphene citrate once daily for 5 days in Cycle 2 and 3 (each cycle = approximately 1 month).
Study NCT01954485 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dental implant placement with a final prosthetic abutment
Study NCT01954485 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dental implant placement with a final prosthetic abutment
Study NCT03964896 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey
Description: Complete survey
Study NCT03964896 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study NCT03964896 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-Based Intervention
Description: Receive telephone calls
Study NCT03204006 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine preinduction
Study NCT03204006 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sterile saline
Description: normal saline preinduction
Study NCT02180659 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sublingual buprenorphine tablets
Study NCT02180659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine implant
Study NCT02180659 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo implants
Study NCT02180659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sublingual placebo tablets
Study NCT03721614 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BioMime™ Morph - Sirolimus Eluting Coronary Stent System
Description: Study Device :- BioMime™ Morph - Sirolimus Eluting Coronary Stent System Approximately 200 patients will be randomly enrolled in a 2:1 ratio \[BioMime™ Morph (n=133) vs. XIENCE family (n=67)\].
Study NCT03721614 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Xience family Everolimus Coronary Stent Systems
Description: Active Control Device :- Xience family Everolimus Coronary Stent Systems Approximately 200 patients will be randomly enrolled in a 2:1 ratio \[BioMime™ Morph (n=133) vs. XIENCE family (n=67)\].
Study NCT03841591 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Women with GDM will receive insulin and tailored according to their blood glucose levels to achieve glycemic control. Starting dose will be 30unit (20 unit intermediate dose + 10 unit rapid acting insulin) in the morning and before breakfast). In the 2nd trimester, we will start with half of the previous dose and if post dinner glucose level remain elevated additional injection of rapid acting insulin will be given just prior to dinner. If fasting glucose is elevated, intermediate acting insulin can be given along with the dinner dose of rapid acting insulin.
Study NCT03841591 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Women with GDM will receive metformin and tailored according to their blood glucose levels to achieve glycemic control. They will receive an initial metformin dose of 500 mg once or twice daily (according to initial blood glucose level) with food and increased 500 mg every one or two weeks toward targets or up to a maximum daily dose of 2500 mg divided doses with each meal.
Study NCT03841591 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Assessment of weight gain
Description: Body weight will be measured monthly from the start of treatment till delivery.
Study NCT01863394 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Screening by mothers
Study NCT01863394 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active comparator: Screening by community health workers
Study NCT02986048 — intervention group
Intervention type: OTHER
Intervention: Proton Beam Therapy
Description: Intervention is not assigned. Only patient data is being collected
Study NCT04281147 — intervention group
Intervention type: DRUG
Intervention: Radium-223 dichloride (Xofigo, BAY88-8223)
Description: Follow clinical administration
Study NCT03878368 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sulforaphane
Description: Intervention soup with dietary sulforaphane
Study NCT03878368 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Control soup without dietary sulforaphane
Study NCT00322517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SU014813
Description: 100 mg capsule/day for 6 cycle of 21 days
Study NCT03602976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic Acid
Description: weight-based dosing
Study NCT03288428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalbuphine
Description: patient controlled analgesia with Nalbuphine
Study NCT03288428 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: patient controlled analgesia with Morphine
Study NCT01909999 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suture
Description: Soft tissues sutures were done using absorbable polygalactin 910 suture.